Literature DB >> 31532006

A novel normalization for amide proton transfer CEST MRI to correct for fat signal-induced artifacts: application to human breast cancer imaging.

Ferdinand Zimmermann1,2, Andreas Korzowski1, Johannes Breitling1,2,3, Jan-Eric Meissner1, Patrick Schuenke1, Lisa Loi4,5, Moritz Zaiss6, Sebastian Bickelhaupt7, Sarah Schott8, Heinz-Peter Schlemmer4,5, Daniel Paech4, Mark E Ladd1,2,5, Peter Bachert1,2, Steffen Goerke1.   

Abstract

PURPOSE: The application of amide proton transfer (APT) CEST MRI for diagnosis of breast cancer is of emerging interest. However, APT imaging in the human breast is affected by the ubiquitous fat signal preventing a straightforward application of existing acquisition protocols. Although the spectral region of the APT signal does not coincide with fat resonances, the fat signal leads to an incorrect normalization of the Z-spectrum, and therefore to distorted APT effects. In this study, we propose a novel normalization for APT-CEST MRI that corrects for fat signal-induced artifacts in the postprocessing without the need for application of fat saturation schemes or water-fat separation approaches.
METHODS: The novel normalization uses the residual signal at the spectral position of the direct water saturation to estimate the fat contribution. A comprehensive theoretical description of the normalization for an arbitrary phase relation of the water and fat signal is provided. Functionality and applicability of the proposed normalization was demonstrated by in vitro and in vivo experiments.
RESULTS: In vitro, an underestimation of the conventional APT contrast of approximately -1.2% per 1% fat fraction was observed. The novel normalization yielded an APT contrast independent of the fat contribution, which was also independent of the water-fat phase relation. This allowed APT imaging in patients with mamma carcinoma corrected for fat signal contribution, field inhomogeneities, spillover dilution, and water relaxation effects.
CONCLUSION: The proposed normalization increases the specificity of APT imaging in tissues with varying fat content and represents a time-efficient and specific absorption rate-efficient alternative to fat saturation and water-fat separation approaches.
© 2019 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  APT; AREX; CEST; MRI; cancer; fat suppression; mamma carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31532006     DOI: 10.1002/mrm.27983

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  3 in total

1.  Using amide proton transfer-weighted MRI to non-invasively differentiate mismatch repair deficient and proficient tumors in endometrioid endometrial adenocarcinoma.

Authors:  Yuan Li; Xinyu Liu; Xiaoqi Wang; Chengyu Lin; Yafei Qi; Bo Chen; Hailong Zhou; Qiaoling Wu; Jing Ren; Jia Zhao; Junjun Yang; Yang Xiang; Yonglan He; Zhengyu Jin; Huadan Xue
Journal:  Insights Imaging       Date:  2021-12-11

Review 2.  Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors.

Authors:  Jinyuan Zhou; Moritz Zaiss; Linda Knutsson; Phillip Zhe Sun; Sung Soo Ahn; Silvio Aime; Peter Bachert; Jaishri O Blakeley; Kejia Cai; Michael A Chappell; Min Chen; Daniel F Gochberg; Steffen Goerke; Hye-Young Heo; Shanshan Jiang; Tao Jin; Seong-Gi Kim; John Laterra; Daniel Paech; Mark D Pagel; Ji Eun Park; Ravinder Reddy; Akihiko Sakata; Sabine Sartoretti-Schefer; A Dean Sherry; Seth A Smith; Greg J Stanisz; Pia C Sundgren; Osamu Togao; Moriel Vandsburger; Zhibo Wen; Yin Wu; Yi Zhang; Wenzhen Zhu; Zhongliang Zu; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2022-04-22       Impact factor: 3.737

3.  Comparative Study of Amide Proton Transfer Imaging and Intravoxel Incoherent Motion Imaging for Predicting Histologic Grade of Hepatocellular Carcinoma.

Authors:  Baolin Wu; Fei Jia; Xuekun Li; Lei Li; Kaiyu Wang; Dongming Han
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.